Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with
New paper in The Lancet Neurology proposes the first iteration of a research framework for defining and staging Parkinson s disease (PD) based on biology,.
Researchers have discovered that a protein called phosphorylated α-synuclein, which is associated with several neurodegenerative diseases such as Parkinson's disease and Lewy body dementia, is also involved in the normal processes of how neurons communicate with each other in a healthy brain.
In the development of Parkinson's disease (PD), the changes that will lead to neurodegeneration take place in the brain long before patients show any symptoms.